Humira's dominance slips but remains strong as biosimilars gain traction in the evolving adalimumab market

Leerink Partners analyst David Risinger has reiterated their bullish stance on ABBV stock, giving a Buy rating yesterday.Stay Ahead of the Mark...

Visa, AbbVie, Analog Devices and Precipio are included in this Analyst Blog.

When AbbVie (ABBV) stock spiked above $205 in November 2024, the rally did not last long. ABBV stock fell to as low as $165 weeks later. The drug manufacturer stock is on sale for several reasons. AbbVie terminated its Alector collaboration agreement ...

We recently published a list of 10 Best Dividend Kings Stocks to Invest in Now. In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against other best dividend king stocks to invest in now. Investing in dividend stocks has been a focal point for investors for several years. […]